Cerevel Therapeutics (CERE) Stock Forecast, Price Target & Predictions
CERE Stock Forecast
Cerevel Therapeutics stock forecast is as follows: an average price target of $33.50 (represents a -25.49% downside from CERE’s last price of $44.96) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
CERE Price Target
The average price target for Cerevel Therapeutics (CERE) is $33.50 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $40.00 to $27.00. This represents a potential -25.49% downside from CERE's last price of $44.96.
CERE Analyst Ratings
According to 2 Wall Street analysts, Cerevel Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for CERE stock is 0 'Strong Buy' (0.00%), 1 'Buy' (50.00%), 1 'Hold' (50.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Cerevel Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Dec 06, 2022 | J.P. Morgan | $40.00 | $28.01 | 42.81% | -11.03% | |
| Aug 15, 2022 | Graig Suvannavejh | Mizuho Securities | $27.00 | $34.86 | -22.55% | -39.95% |
The latest Cerevel Therapeutics stock forecast, released on Dec 06, 2022 by J.P. Morgan company, set a price target of $40.00, which represents a 42.81% increase from the stock price at the time of the forecast ($28.01), and a -11.03% decrease from CERE last price ($44.96).
Cerevel Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $44.96 | $44.96 | $44.96 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of Cerevel Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Cerevel Therapeutics's last price of $44.96. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Dec 07, 2023 | Piper Sandler | Neutral | Downgrade | |
| Sep 26, 2022 | Wells Fargo | Overweight | Initialise |
Cerevel Therapeutics's last stock rating was published by Piper Sandler on Dec 07, 2023. The company Downgrade its CERE rating from "null" to "Neutral".
Cerevel Therapeutics Financial Forecast
Cerevel Therapeutics Revenue Forecast
| Oct 25 | Jul 25 | Mar 25 | Dec 24 | Oct 24 | Jul 24 | Mar 24 | |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| # Analysts | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
Cerevel Therapeutics's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. CERE's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Cerevel Therapeutics EBITDA Forecast
| Oct 25 | Jul 25 | Mar 25 | Dec 24 | Oct 24 | Jul 24 | Mar 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
undefined analysts predict CERE's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Cerevel Therapeutics's previous annual EBITDA (undefined) of $NaN.
Cerevel Therapeutics Net Income Forecast
| Oct 25 | Jul 25 | Mar 25 | Dec 24 | Oct 24 | Jul 24 | Mar 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| Net Income | - | - | - | - | - | - | - |
| Avg Forecast | $-138.02M | $-132.58M | $-130.76M | $-154.37M | $-131.67M | $-137.12M | $-119.50M |
| High Forecast | $-138.02M | $-132.58M | $-130.76M | $-154.37M | $-131.67M | $-101.65M | $-119.50M |
| Low Forecast | $-138.02M | $-132.58M | $-130.76M | $-154.37M | $-131.67M | $-167.85M | $-119.50M |
| Surprise % | - | - | - | - | - | - | - |
Cerevel Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. CERE's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Cerevel Therapeutics SG&A Forecast
| Oct 25 | Jul 25 | Mar 25 | Dec 24 | Oct 24 | Jul 24 | Mar 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
Cerevel Therapeutics's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to CERE last annual SG&A of $NaN (undefined).
Cerevel Therapeutics EPS Forecast
| Oct 25 | Jul 25 | Mar 25 | Dec 24 | Oct 24 | Jul 24 | Mar 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - |
| Avg Forecast | $-0.76 | $-0.73 | $-0.72 | $-0.85 | $-0.72 | $-0.76 | $-0.66 |
| High Forecast | $-0.76 | $-0.73 | $-0.72 | $-0.85 | $-0.72 | $-0.56 | $-0.66 |
| Low Forecast | $-0.76 | $-0.73 | $-0.72 | $-0.85 | $-0.72 | $-0.92 | $-0.66 |
| Surprise % | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, Cerevel Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to CERE previous annual EPS of $NaN (undefined).
Cerevel Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| VTYX | Ventyx Biosciences | $2.27 | $33.86 | 1391.63% | Buy |
| HOWL | Werewolf Therapeutics | $1.54 | $12.00 | 679.22% | Buy |
| GPCR | Structure Therapeutics | $28.25 | $99.00 | 250.44% | Buy |
| TERN | Terns Pharmaceuticals | $5.80 | $18.67 | 221.90% | Buy |
| IGMS | IGM Biosciences | $6.40 | $18.67 | 191.72% | Buy |
| CGEM | Cullinan Oncology | $12.27 | $34.00 | 177.10% | Buy |
| MLYS | Mineralys Therapeutics | $12.80 | $30.00 | 134.38% | Buy |
| STOK | Stoke Therapeutics | $11.32 | $26.50 | 134.10% | Buy |
| APLS | Apellis Pharmaceuticals | $33.32 | $70.80 | 112.48% | Buy |
| SWTX | SpringWorks Therapeutics | $36.81 | $76.00 | 106.47% | Buy |
| DAWN | Day One Biopharmaceuticals | $12.67 | $24.00 | 89.42% | Buy |
| RNA | Avidity Biosciences | $31.35 | $59.00 | 88.20% | Buy |
| DSGN | Design Therapeutics | $6.35 | $9.67 | 52.28% | Buy |
| RVMD | Revolution Medicines | $44.39 | $65.67 | 47.94% | Buy |
| NUVL | Nuvalent | $82.65 | $114.80 | 38.90% | Buy |
| BPMC | Blueprint Medicines | $90.46 | $122.60 | 35.53% | Buy |
| TVTX | Travere Therapeutics | $17.13 | $21.75 | 26.97% | Buy |
| IKNA | Ikena Oncology | $1.53 | $1.33 | -13.07% | Buy |